|A unique collection of 81 Cardioprotective natural compounds for high throughput screening (HTS) and high content screening (HCS).|
|Catalog No:||Bb1313|| Cardioprotective Compound Library
|Size:||1mg/well * 81 Compounds|
2mg/well * 81 Compounds
1. Astragaloside IV has been shown to protect the myocardium against ischemia/reperfusion injury, it also has beneficial effect in H/R-induced injury may be related to normalization of SR Ca2+ pump expression and, thus, it may prevent the depression in SR Ca2+ handling.
2. Astragaloside IV can reduce phosphorylation of JNK and ERK1/2 induced by complement membranous attack complex, the mechanism of Astragalus membranaceus in the treatment of membranous nephropathy (MN) may be related to its attenuation of podocyte injury through regulation of cytoskeleton and mitogen activated protein kinase.
3. Astragaloside IV can reduce blood pressure and triglyceride levels in fructose-fed rats and high dose of astragaloside IV also improves glucose tolerance and endothelium-dependent vasorelaxation, it may be useful in ameliorating food-induced metabolic syndrome.
4. Astragaloside IV attenuates inflammatory cytokines by inhibiting TLR4/NF-кB signaling pathway in isoproterenol-induced myocardial hypertrophy, and attenuates Toll-like receptor 4 expression via NF-κB pathway under high glucose condition in mesenchymal stem cells.
5. Astragaloside IV can inhibit adenovirus replication and apoptosis in A549 cells in vitro.
6. Astragaloside IV has anti-fibrotic effect against systemic sclerosis.
1. Cyclovirobuxine D(CVB-D) has been widely used for treatment of cardiac insufficiency and arrhythmias in China, the antiarrhythmic and proarrhythmic potential of this drug might be concerned with prolongation of action potential duration and QT interval.
2. Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction and supports the potential for cyclovirobuxine D as a new therapy for heart failure.
3. Cyclovirobuxine D can induce autophagy in the MCF-7 human breast cancer cell line, CVB-D-induced autophagy and decrease in cell viability could be blocked by 3-methyladenine, a well-established autophagy inhibitor, moreover.
4. Cyclovirobuxine D can attenuate the phosphorylation of Akt and mTOR, two pivotal suppressors in autophagy pathways;these findings may support the potential utility of autophagy inducers in cancer treatment.
5. Cyclovirobuxine D shows vasorelaxant effect.
1. Salidroside has anti-tumor action.
2. Salidroside has antidepressant and anxiolytic actions.
3. Salidroside has Anticancer action through inhibiting JAK2/STAT3 signaling pathway.
4. Salidroside alleviates the pulmonary symptoms of paraquat-induced acute lung injury, at least partially, by repressing inflammatory cell infiltration and the expression of TGF-β1 resulting in delayed lung fibrosis.
5. Salidroside has potent antioxidant action against oxidative stress-induced cell apoptosis, may be a potential therapeutic agent for treating or preventing neurodegenerative diseases implicated with oxidative stress.
6. Salidroside has shown cardioprotective effects in vivo, it has protective effect against hypoxia-induced cardiomyocytes necrosis and apoptosis by increasing HIF-1α expression and subsequently up-regulating VEGF levels.
1. Rosiridin has cardioprotective activity.
1. Sophocarpine and matrine exert anti-cachectic effects probably through inhibition of TNF-alpha and IL-6 and prevent cachexia-related symptoms induced by colon26 adenocarcinoma in mice.
2. Sophocarpine injection (called the Kangke injection) has been demonstrated to have significant antivirus effects against coxsackievirus B3 and therapeutic effects for viral myocarditis in clinical.
3. Sophocarpine exerts anti-inflammatory activity in vitro, and it may attribute to the inhibition of iNOS and COX-2 expressions via down-regulation of the JNK and p38 MAP kinase signal pathways and inhibition of NF-κB activation.
4. Sophocarpine can alleviate liver fibrosis mainly by inhibiting the TLR4 pathway, it may be a potential chemotherapeutic agent for chronic liver diseases.
5. Sophocarpine can ameliorate the ischemic injury induced by transient focal cerebral ischemia in rats and that this neuroprotective effect may be related to the anti-ASIC1 channel and anti-apoptotic action of sophocarpine.
6. Sophocarpine can alleviate hepatocyte steatosis and the potential mechanism may be the activated signaling pathway of AMPK.